Laboratory medicine – Vet Clin Path Journal Sat, 25 Jun 2022 03:01:19 +0000 en-US hourly 1 Laboratory medicine – Vet Clin Path Journal 32 32 Dorothy Louise (Jayes) Stewart Obituary Fri, 24 Jun 2022 21:48:18 +0000

Dorothy Louise (Jayes) Stewart of Dennis Port died on June 22, 2022, after a valiant battle with primary peritoneal cancer. Born May 21, 1945 in Northampton, Massachusetts, she was the daughter of the late Frederick John Jayes and the late Grace Esther Ewing Jayes. She attended schools in Easthampton, Massachusetts, and graduated from Easthampton High School in 1963. She graduated from the University of Massachusetts Amherst (don’t pronounce the “H”) with a Bachelor of Science in Science from medical laboratory. She is survived by the love of her life, her husband of fifty-six years, Bruce Campbell Stewart of Dennis Port, Massachusetts, her daughter Melissa Anne Stewart and her husband Gerard Tynes Fairley of Acton, Massachusetts, and her son, Douglas Bruce Stewart and his wife Jessica Cloutier Stewart of Pownal, Maine, and treasured grandchildren Colin Campbell, Claire Mary and Caroline Grace Stewart. She will be missed by her Yorkie, Buster. She was predeceased by her brother, David Alexander Jayes of Brewster, Massachusetts.

Bruce and Dottie began their married life in East Hartford, Connecticut, where Dottie worked at Hartford Hospital and the Traveler’s Insurance Company Medical Laboratory. In 1970 they returned to western Massachusetts and settled in Southampton. In 1971 she opened an in-office medical laboratory for a group of doctors who became Northampton Internal Medicine. As the practice and lab grew, the lab was taken over by Bioran Medical Laboratory and became Quest Diagnostics. At the lab, Dottie not only provided diagnostic expertise, but she always had flowers, usually roses, on the reception counter. She became known as the Flower Lady of the Laboratory and also for her gardens in Southampton. When Dottie left the lab in 2006, she had become the technical supervisor for all Quest Diagnostic facilities in western Massachusetts. Dottie was actively involved in the activities of the First Congregational Church of Southampton, serving as a member of Ladies Aid, Trustees, Christian Education Committee, Research Committee and as Co-Superintendent of the School of the Church. She was a member of the Southampton Women’s Club, a Girl Scout leader, an avid bridge player and a gardener.

In 2008, Bruce and Dottie retired to their summer home on Cape Cod. Here Dottie pursued her love of gardening and especially roses. She became known again as the Flower Lady and was always asked questions about gardening. Her roses have won awards at local rose shows. She was a member of the West Dennis Garden Club, Dennis-Yarmouth Women’s Club, Cape Cod Rose Society, and Cape Cod Hydrangea Society, and played bridge at every opportunity. She was also a volunteer with the Dennis Police Department.

Visiting hours will be at Doane, Beal and Ames Funeral Home, 729 Rt. 134, South Dennis on Tuesday, June 28, 2022 from 1 to 3 p.m. with a service at 3 p.m. Burial is at the convenience of the family at Brookside Cemetery, Easthampton, Massachusetts. In lieu of flowers, please make a donation to the American Cancer Society in honor of Dorothy. To leave messages of condolence for Dottie’s family, please visit

Posted on June 24, 2022

Posted in Cape Cod Times

MediciNova Announces Research Collaboration on MN-001 (tipelukast) with Juntendo University School of Medicine in Tokyo, Japan Wed, 22 Jun 2022 23:00:00 +0000

MediciNova, Inc.

LA JOLLA, Calif., June 22, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (code number: 4875), today announced the initiation of a comprehensive research collaboration with Juntendo University, School of Medicine (2-1-1 Hongo, Bunkyo-Ku, Tokyo, Japan) to evaluate the mechanism of action of MN-001 (tipelukast) on lipid metabolism and metabolic syndrome.

The main collaborator is Takashi Mitsui MD, Ph.D., Professor and Chairman of the Department of Laboratory Medicine, a recognized expert in lipid metabolism who specializes in dyslipidemia and metabolic syndrome.

Kazuko Matsuda, MD, Ph.D., MPH, Medical Director of MediciNova, Inc, commented, “MN 001 is a new orally administered compound with multiple mechanisms, and its anti-fibrotic and anti-inflammatory effects have been observed in several animal model studies. It has also been observed to reduce serum triglyceride levels in patients with elevated serum triglyceride levels in several clinical trials conducted previously. In the Phase 2 trial in NASH/NAFLD patients with hypertriglyceridemia, MN-001 (tipelukast) reduced serum triglycerides, increased high-density lipoproteins (HDL-C), and reduced low-density lipoproteins ( LDL) during the 12-week treatment period. Additionally, improvements in serum lipid profile were more significant in patients with type 2 diabetes/prediabetes. We believe this research collaboration will provide new insights into the mechanism of action of MN-001 in the area of ​​lipid metabolism and metabolic syndrome and identify conditions that would benefit from MN-001 treatment.

About MN-001 (tipelukast)

MN-001 (tipelukast) is a novel, orally bioavailable, small-molecule compound thought to exert its effects through several mechanisms to produce its anti-inflammatory and anti-fibrotic activity in preclinical models, including the antagonism of leukotriene (LT) receptors, inhibition of phosphodiesterases (PDE) (mainly 3 and 4) and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in the development of fibrosis, and the inhibitory effect of MN-001 on 5-LO and 5-LO/LT pathway is a new approach to treat the fibrosis. MN-001 has been shown to downregulate the expression of genes that promote fibrosis, including LOXL2, collagen type 1, and TIMP-1. MN-001 has also been shown to downregulate the expression of genes that promote inflammation, including CCR2 and MCP-1. Additionally, MN-001 has been shown to inhibit triglyceride synthesis in hepatocytes by inhibiting arachidonic acid uptake.

About MediciNova

MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad portfolio of novel small molecule therapies for inflammatory, fibrotic and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3 ready for progressive multiple sclerosis ( SEP). MN-166 (ibudilast) has been studied in a phase 2 trial in patients at risk of developing acute respiratory distress syndrome (ARDS) and is also being evaluated in phase 2 trials for glioblastoma and drug addiction. substance. MN-001 (tipelukast) has been evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and is in preparation for a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD). MediciNova has a strong track record of obtaining investigator-sponsored clinical trials funded by government grants.

Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding the future development and effectiveness of MN-166, MN-001, MN-221 and MN-029. These forward-looking statements may be preceded, followed or otherwise include the words “believes”, “expects”, “anticipates”, “intends”, “estimates”, “projects”, “may”, “could”. ‘, ‘may’, ‘will’, ‘would’, ‘consider’, ‘plan’ or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risks of obtaining a future partner or grant for the development of MN-166, MN-001, MN -221, and MN-029 and the risks of raising sufficient capital if needed to fund MediciNova’s operations and its contribution to clinical development, the risks and uncertainties inherent in clinical trials, including the potential cost, expected schedule, and risks associated with clinical trials designed to meet FDA requirements the direction and viability of further development considering these factors, the risks of developing and commercializing the product , uncertainty as to whether clinical trial results will be predictive of results at later stages of product development, risk of delay ds or failure to obtain or maintain regulatory approval, risks associated with the use of third parties to sponsor and fund clinical trials, risks regarding information, intellectual property rights in product candidates and the ability to defend and to enforce these intellectual property rights, the risk of default by third parties on which MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as intended, the risk of increased costs and delays due delays in the initiation, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of anticipated filings with regulatory authorities, MediciNova’s collaborations with third parties, the availability of funds to complete product development plans and the MediciNova’s ability to obtain third-party funding for the programs and to raise sufficient capital if needed, and the other risks and uncertainties described in MediciNova’s filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 202 1 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intention or obligation to revise or update these forward-looking statements.

Geoff O’Brien
vice president
MediciNova, Inc.

Oxford BioDynamics Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) Now Available in the UK Tue, 21 Jun 2022 06:16:02 +0000

Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch® 3D genomics platform, announced that its flagship clinical blood test for Checkpoint Inhibitor Response (CiRT) is now available to private physicians considering ICI therapy for their patients in the UK.

This press release is multimedia. See the full version here:

Prediction of EpiSwitch® CiRT response before treatment (Graphic: Business Wire)

First-of-its-kind EpiSwitch CiRT blood test predicts cancer patient’s likelihood of response to widely used therapeutic class – ICIs – including anti-PD-L1 and anti-PD-1 immunotherapies . Using a routine blood test, rather than an invasive biopsy, CiRT provides rapid, personalized advice to the doctor on expected efficacy, allowing for a more informed decision to start or continue treatment.

The robust EpiSwitch qPCR blood test demonstrated best-in-class performance, with high sensitivity (93%), specificity (82%), accuracy (85%) and a significant negative predictive value (NPV) of 93% [1]across multiple ICIs from multiple pharmaceutical companies and over 15 key oncology indications, including melanoma and lung cancer.

This UK expansion follows encouraging early adoption by early adopters of EpiSwitch CiRT in the US, where it was first launched in February 2022 as a laboratory developed test (LDT). The CiRT will initially be available as an LDT to private healthcare providers in the UK. It is only available to licensed physicians.

An estimated 2.9 million people were living with cancer in the UK in 2020, a prevalence rate expected to reach 4 million by 2030 (Macmillan Cancer Support). It is estimated that approximately 350,000 people are diagnosed each year, or more than 1,000 new cases per day (Cancer research in the UK).

Despite the powerful potential efficacy of ICI [2], they have been estimated to be ineffective for up to 70% of treated patients. The situation is exacerbated by the fact that ICIs are among the most expensive drugs in the world. The UK’s best-selling ICI has a list price of £84,000 per patient treatment for the drug alone.

The NHS and private healthcare systems in the UK could save significant sums, estimated at almost £1billion, by avoiding or reducing the rate at which ineffective treatments are given, through simple personalized testing. Savings to the US healthcare system could amount to more than $10 billion.

Dr Geoff Higgins, Honorary Consultant Clinical Oncologist, Oxford University Hospitals NHS Foundation Trust, said: “Immune checkpoint inhibitors are a great advance in cancer treatment, but since many patients fail to respond and the treatment can frequently cause significant side effects, there is a pressing need for robust response biomarkers. The current PD-L1 IHC standard lacks the accuracy desired by many oncologists. There is a significant unmet clinical need to better predict response to ICI for which EpiSwitch CiRT promises to be a valuable addition.”

Dr Simon Lord, Consultant Medical Oncologist, Oxford University Hospitals NHS Foundation Trust, commented: “There are significant limitations, with current routine IHC PDL-1 testing processes not being highly discriminatory in terms of benefit to some patients for whom immunotherapy is indicated. EpiSwitch CiRT has the potential to solve this testing problem with the introduction of a specific and precise IO [immuno-oncology] response test. There is a great advantage in having a liquid biopsy tool that is less invasive than tumor sampling and can be reassessed longitudinally, while being under treatment at multiple times.

OBD CEO Jon Burrows added: “We understand that in order to provide the highest quality care to cancer patients, clinicians must be able to base their treatment choice decision on meaningful and accurate data. We have already seen in the United States that a simple blood test, such as CiRT, which can predict patient response to ICI, could quickly become an essential tool for clinicians. We are proud to now make it available to UK patients as well. Although initially this will only be available to private healthcare providers, we are also aiming to expand availability through the NHS.

OBD recently presented important clinical utility data on the EpiSwitch CiRT clinical test’s prediction of patient response to ICI therapies, at the American Society of Clinical Oncologists (ASCO 2022) Annual Meeting in Chicago, IL . The test has been very well received by oncologists and healthcare providers around the world [3]. OBD will be present and will continue to present new data at the ESMO 2022 Congress (Paris) from September 9 to 13, 2022.

To learn more about EpiSwitch CiRT and to order the test, please visit

Learn more about the importance of the recently launched CiRT test here.

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for checkpoint inhibitor treatments in immuno-oncology (IO), launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Bay Kit.

The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can construct molecular diagnostic classifiers for treatment response prediction, patient prognosis, disease diagnosis and subtyping, and monitoring of residual disease in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with major pharmaceutical companies and leading institutions, including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.

The company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic assays, bioinformatics tools for 3D genomics, and an expert-curated 3D genome knowledge base comprising hundreds of millions of data points from more than 10,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and listed on the AIM of the London Stock Exchange. It also has a sales office in Gaithersburg, MD, USA and a reference laboratory in Penang, Malaysia.

For more information, visit the Company’s website, www.oxfordbiodynamics.comor follow Twitter Where LinkedIn.


[1] Hunter E., et al. Development and Validation of Predictive Blood Biomarkers for Response to PD-(L)-1 Checkpoint Inhibitors: Evidence for a Universal Systemic Core of 3D Immunogenetic Profiling in Multiple Oncology Indications. MedRxiv (2021).

[2] Robert, C. A decade of immune checkpoint inhibitors in the treatment of cancer. Nat Common 11, 3801 (2020).

[3] Oxford BioDynamics PLC. Oxford BioDynamics’ simple blood test that predicts patient response to immune checkpoint inhibitors was well received at ASCO 2022, June 14, 2022.

About EpiSwitch®

The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.

Built on more than 10 years of research, EpiSwitch® is Oxford Biodynamics’ award-winning proprietary platform that enables the screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing over 10,000 samples in 30 disease areas, and scaled to practice.

In addition to stratifying patients based on anticipated clinical outcomes, EpiSwitch® data offers insights into systems biology and physiological manifestation of disease beyond the reach of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration into biomarker discovery and clinical development with major pharmaceutical companies.

Davao City invests in health Sun, 19 Jun 2022 06:23:26 +0000

Covid-19 Cluster Clinic (Photo by Davao City Information Office)

Inauguration of the Mental Wellness Center for the Homeless (Photo by CIO)

Inauguration of the Mental Wellness Center for the Homeless (Photo by CIO)

Los Amigos Molecular Laboratory (photo by IOC)

Los Amigos Molecular Laboratory (photo by IOC)

Marilog District Hospital (Photo by CIO)

Marilog District Hospital (Photo by CIO)

In an effort to strengthen Davao City’s health care sector for its constituents, the city government, under the leadership of outgoing Mayor and Vice President-elect Sara Duterte-Carpio, has prioritized a number investments in the field of health during its consecutive elections. tenure for the past six years.

Some of the important health projects were continued during the height of the Covid-19 pandemic, namely the Covid-19 cluster clinics, the mental well-being center, the intervention center for children with special needs of Davao and Davao Public Hospital.

Covid-19 cluster clinics

As part of Davao City’s Covid-19 response, the Local Government Unit (LGU) has partnered with Reach Health-US Agency for International Development (USAid) to construct the Covid-19 Cluster Clinics (CCC ).

It aims to provide 24/7 service to Dabawenyos coronavirus related needs. The first CCC was in Dona Vicenta Village but eventually moved to Sta. Ana Health Center. The city government plans to continue expanding the clinics.

At present, the CCC in Calinan is 95% complete and another in Tibungco is in progress.

Mental Wellness Center

The Mental Wellness Center for the Homeless was also materialized at the height of the pandemic to address the problem of street dwellers with mental health issues who may be exposed to Covid-19.

The center, which cost 26 million pesos, is located in the complex of the Southern Philippines Medical Center (SPMC) – Institute of Psychiatry and Behavioral Medicine and was inaugurated on January 21, 2022.

The facility houses rescued street pumpers where they receive food, clothing, shelter and medical care tailored to their needs. In the facility, patients can also participate in different activities like music, arts, games and sports to develop their skills.

Apart from this, the Mental Wellness Center also serves as an outpatient counseling center for Dabawenyos who need psychiatric care.

During the inauguration of the center, the vice-president-elect expressed the hope that the center will help raise awareness and fight the stigma associated with mental health.

“The establishment of the Davao City Mental Health Center for the Homeless is a welcome initiative by the local government, not only to provide a comfortable refuge for our homeless and mentally ill residents, but also to combat the stigma surrounding health mental health and community awareness,” said Duterte-Carpio.

Davao City Special Needs Children’s Intervention Center

On the other hand, the long-awaited Davao City Special Needs Intervention Center and Davao City Public Hospital were finally given the go-ahead this year after suffering setbacks due to the Covid-19 pandemic. 19.

During his State of the City address on March 17, 2022, Duterte-Carpio said the Special Needs Response Center began construction with a budget of 70 million pesos.

This one-of-a-kind center will provide free early intervention, special education and occupational therapy, speech therapy and physiotherapy programs to children and youth with special needs.

“With more and more children being diagnosed with special needs and given the prohibitive cost of therapies and intervention programs, we continued to establish the Davao City Special Needs Children Intervention Center “Duterte-Caprio said.

Due to be completed next year, the center will house special facilities including a physiotherapy room, an aquatherapy pool, an occupational therapy sensory gym and a speech therapy room.

Davao City Public Hospital

In order to expedite the construction of Davao Public Hospital, the Mayor issued Executive Order No. 41 of 2021 establishing an Executive Committee (Execom) and Technical Working Group (TWG) to oversee the project.

Currently, the LGU has allocated a budget of P250,000,000 to start the development of the land of the city hospital, which will be built on the land of the University of the Philippines-Mindanao at Barangay Mintal.

It will be a level III training and Covid-19 response hospital that will provide services for all kinds of illnesses, diseases, injuries and deformities.

Other health initiatives

Another hospital was also opened during Duterte-Carpio’s tenure. Marilog District Hospital received its operating license from the Ministry of Health in February 2021 and has a capacity of 0 beds, 14 medical wards and 73 medical and non-medical staff.

These are just a few of the important projects that Duterte-Carpio has invested in Davao City’s health sector to provide better services and treatment to Dabawenyos of all ages.

But the outgoing mayor has also built other key health facilities, including the construction of 84 health centers and essential Covid-19-related projects that complement the city’s overall effective response to the pandemic.

These are the Los Amigos Davao Laboratory approved by the Department of Health (DOH) to process RT-PCR swab tests and the P12 million Davao City Crematorium for proper handling of the remains of the victims. of Covid-19.

The mayor also established the Davao City Covid-19 Task Force led by the mayor herself, which oversees the city’s Covid-19 response, from enforcing safety and security measures to facilitating the deployment of the vaccination.

Toward the start of his second term as mayor in 2017, Duterte-Carpio expanded the existing Lingap Para sa Mahirap program into a one-stop medical assistance called Pagkalinga sa Bayan.

The Davao LGU’s Lingap Para sa Mahirap is financial aid for hospital bills and medical services, while the Pagkalinga sa Bayan combines aid from the Philippine Charity Sweepstakes Office (PCSO), Department of Social Welfare and Development ( DSWD), PhilHealth, Philippine Amusement and Gaming Corporation (Pagcor) and the Lingap program.

“We initiated this because patients and their families have to go to different offices to apply for financial aid,” the mayor told the inauguration of the Pagkalinga sa Bayan at SPMC in 2017.

According to the mayor, thanks to the ingenuity of the Pagkalinga sa Bayan of Davao LGU, the program has been replicated nationwide as Malasakit centers.

In 2021, four Lingap satellite offices were opened at Marilog District Hospital, Bunawan District Hall, Toril Gym and Paquibato Proper Barangay Hall. In November of the same year, the online and contactless Lingap platform for inquiries and applications was launched via Facebook.

Some of the assistive and medical services that may be acquired under the Lingap program include hospital, funeral and funeral assistance, medical and laboratory procedures, maintenance medications, prosthetic sensory and visual aids, reconstructive surgery for orofacial cleft and other special cases.

Control assistance for inpatient, outpatient and emergency patients is also included.

These projects and programs were carried out by the LGU despite the threats of the Covid-19 pandemic.

Over the past six years, the city government has implemented several investments and initiatives to improve the health sector in the city. This has allowed the Dabawenyos to have better access to quality health services.

AACC Elects New Officers for Terms Beginning in August 2022 Fri, 17 Jun 2022 13:59:12 +0000

The AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that Octavia Peck Palmer, PhD, FAACC, has been elected to the AACC Board of Directors. as President-Elect from August 2022. Thereafter, she will serve successive terms as President of the Association from August 2023 to July 2024 and as Past President from August 2024 to July 2025. In addition, AACC members elected a new Treasurer and two new Directors to the association’s Board of Directors. They will take office in August 2022 with the new President of the AACC Academy and the new President of the Council of Clinical Laboratory Scientists of the AACC, who will also serve on the Board of Directors.

“I am delighted that the members of the AACC have elected me as the association’s president-elect,” said Dr. Peck Palmer. “In this role, I look forward to working with the leadership, staff and members of the AACC to continue to equip laboratory medicine professionals to successfully adapt to complex challenges and increased demands of today’s health care. I strive to build on the organization’s rich history of raising public awareness of laboratory medicine; provide multi-faceted educational resources; advocate for health equity; lead global outreach efforts that empower resource-constrained clinical laboratories; and drive advances in the field that improve patient care. »

Dr. Peck Palmer is an Associate Professor of Pathology, Critical Care Medicine, and Clinical and Translational Sciences at the University of Pittsburgh School of Medicine. She is the Clinical Chemistry Division Director and Medical Director of Presbyterian and Shadyside Hospitals and University of Pittsburgh Medical Center (UPMC) Automated Testing Laboratories. She is also the Associate Medical Director of the Automated Testing Laboratory at UPMC Children’s Hospital in Pittsburgh.

An active member of the AACC since 2006, Dr. Peck Palmer is currently completing a 3-year term as a member of the association’s Board of Directors. She is Chair of AACC’s Health Equity and Access Division, which she founded, and Chair of AACC’s Diversity, Equity and Inclusion Committee. . She has also held numerous other positions within the association, including as a member of the organizing committee for the 2016 AACC Annual Scientific Meeting and Clinical Laboratory Expo; Member of AACC Basic Education Committee; editor of CLN Daily; and secretary of the AACC’s Division of Clinical and Translational Sciences.


Victoria Zhang, PhD, MBA, DABCC, FAACC, will serve as AACC Treasurer from August 2022 to July 2025.

Dr. Zhang is a professor in the Department of Pathology and Laboratory Medicine at the University of Rochester Medical Center (URMC) in New York City, as well as director of the clinical chemistry division and vice president of clinical enterprise strategy. at URMC. Since joining AACC in 2009, she served as founding chair of the AACC Mass Spectrometry and Separation Sciences Division and the Asia-Pacific Working Group of the AACC Global Lab Quality Initiative. She led the AACC’s effort to publish practical guidance on SARS-CoV-2 antibody testing. In addition, she has served on the AACC Science and Practice Central Committee, the AACC Finance Committee, and as a member of the Organizing Committee for the Annual Scientific Meeting and Exhibition of the AACC clinical laboratory.


Daniel T. Holmes, MD, FRCPC, and Stanley F. Lo, PhD, will serve on the AACC Board of Directors from August 2022 through July 2025. Yusheng Zhu, PhD, DABCC, FAACC, will also serve on the Board of Directors. August 2022-July 2023 as President of AACC Academy, the association’s home for distinguished laboratory experts who shape science in the field. Additionally, Erika Deaton-Mohney, MT (ASCP), CPP, will serve on the Board of Directors from August 2022 to July 2023 as Chair of the Council of Clinical Laboratory Scientists, which guides the activities and programs of the AACC to meet the professional needs of the AACC clinical laboratory scientist. members.

Dr. Holmes is Clinical Professor of Pathology and Laboratory Medicine at the University of British Columbia and Chief and Medical Director of the Department of Pathology and Laboratory Medicine at St. Paul’s Hospital in Vancouver. A member of the AACC since 2005, he currently serves on the AACC Basic Education Committee and served as chair of the AACC Division of Endocrinology.

Dr. Lo is a professor of pathology at the Medical College of Wisconsin and associate director of clinical laboratories at Children’s Wisconsin in Milwaukee. He has been a member of the AACC since 1994 and is currently Chair of the AACC Awards Committee and President Elect of the AACC Pediatric-Maternal-Fetal Division. He also served on the association’s nominating committee, grassroots education committee, and chair of the organizing committee for the 2017 AACC Annual Scientific Meeting and Clinical Laboratory Expo.


AACC members also elected Carmen L. Wiley, PhD, DABCC, FAACC; Robert Fitzgerald, PhD, DABCC (CC and CT), FAACC, NRCC; and Nichole Korpi-Steiner, PhD, DABCC, FAACC, to serve from August 2022 to July 2025 on the association’s nominating committee. The AACC Nominating Committee performs the important task of ensuring that the leadership of the association includes a diverse and highly talented group of individuals who represent the full membership of the AACC.

Dr. Wiley is Clinical Medical Director at Incyte Diagnostics and Medical Director of Clinical Laboratories at Providence Inland Northwest Washington in Spokane, Washington.

Dr. Fitzgerald is a professor in the Department of Pathology at the University of California, San Diego, where he is also director of the toxicology laboratory and associate director of the clinical chemistry laboratory.

Dr. Korpi-Steiner is Associate Professor of Pathology and Laboratory Medicine at the University of North Carolina at Chapel Hill, where she is also Co-Director of Clinical Chemistry and Director of Specialty Chemistry and Point-of-Care Testing.


Dedicated to improving health through laboratory medicine, AACC brings together more than 70,000 clinical laboratory professionals, physicians, researchers and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, laboratory management and other areas of laboratory science is progressing. Since 1948, the AACC has worked to advance common interests in the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit

This news content was set up by WebWire’s editorial staff. Linking is allowed.

Press release distribution and press release distribution services provided by WebWire.

Alice H. Lichtenstein, Distinguished Nutritional Scientist, presents the 2022 ARS Atwater Memorial Lecture: USDA ARS Wed, 15 Jun 2022 14:18:33 +0000

Alice H. Lichtenstein, Distinguished Nutritional Scientist, presents the 2022 ARS Atwater Memorial Lecture

Contact person: Kim Kaplan
Email: Kim Kaplan

WASHINGTON, June 15, 2022 — “Information/Misinformation on nutrition: who is right? Who decides?” is the title of Alice H. Lichtenstein’s 2022 Agricultural Research Service WO Atwater Memorial Lecture, presented virtually today at 10 a.m. at Nutrition 2022, the annual meeting of the American Society of Nutrition.

“Food and nutrition information reaches the public from many sources and in many forms. hampered public health efforts to improve diet quality Our challenge is to come together to engage in productive discussions about how best to communicate the most accurate and timely food and nutrition information available, which will lead ultimately to better overall food quality for all,” Lichtenstein said.

Lichtenstein is renowned for her groundbreaking research on the interaction between diet, particularly fats and oils, and risk factors for cardiovascular disease. His lab was among the first to document the adverse effects of partially hydrogenated hydrogenation (trans) fat on blood lipids. This work helped lay the foundation for the labeling and subsequent banning of partially hydrogenated fats by the United States Food and Drug Administration.

She currently holds the Stanley N. Gershoff Professorship in Nutrition Science and Policy at the Friedman School of Tufts University. She is also Professor of Medicine at Tufts Medical Center and Director of the Cardiovascular Nutrition Laboratory and Senior Scientist at the Jean Mayer USDA Center for Human Nutrition Research on Aging.

Over the years, his research group has focused on food and health issues related to trans fatty acids, soy proteins and isoflavones, sterol/stanol esters, new vegetable oils with different fatty acid profile and glycemic index, mainly in the elderly.

Alice H. Lichtenstein is the 2022 WO Atwater Memorial Speaker.

His recent work has focused on population-based studies to assess the relationships between biomarkers of food intake and risk factors for cardiovascular disease, and the impact of taste perception on food choices and quality of eating. food.

As a highly respected scientist, she has consistently pushed beyond the confines of her lab to bridge the gap between nutritional science and public policy.

For four years, Lichtenstein chaired the public policy committee of the American Society for Nutrition. In addition, she currently serves on the Standing Committee on Evidence Synthesis and Communications on Diet and Chronic Disease Relationships, the Standing Committee for the Dietary Reference Intakes Framework Review, and the Food Council. and Nutrition of the National Academies Division of Health and Medicine. of Science, Engineering and Medicine, and previously served on the Council’s Macronutrient Panel, which helped establish the values ​​used for the Nutrition Facts label now required on all packaged foods and beverages.

Among his many honors and awards are the Conrad A. Elvehjem Award for Public Service in Nutrition, American Society for Nutrition; Hans Fisher Lecture, Department of Nutritional Sciences, Rutgers University; Levy Lecture, American Heart Association; Award for Excellence in Dietetic Guidance, Food and Nutrition Section, American Public Health Association; and 2006 Shape Magazine, one of the ten “women who shaped the world”.

The WO Atwater Memorial Lecture was established by ARS in 1968 to honor the memory of Wilbur Olin Atwater (1844-1907) and to recognize scientists who have made unique contributions to improving food and nutrition people from all over the world. Atwater, considered the father of modern nutrition research and education, was the first head of nutrition surveys for the United States Department of Agriculture. For more information on the WO Atwater lecture, visit

The Agricultural Research Service is the principal internal scientific research agency of the United States Department of Agriculture. Daily, ARS focuses on solutions to agricultural problems affecting America. Every dollar invested in agricultural research translates into $17 of economic impact.

3 physician-researchers named Dean’s Scholars – Washington University School of Medicine in St. Louis Mon, 13 Jun 2022 21:01:56 +0000
Visit the news center

The program helps physicians pursue basic scientific research

University of Washington

The Physician-Scientist Division at Washington University School of Medicine in St. Louis selected three physicians for its third class of Dean’s Fellows. The program provides up to two years of financial support and mentorship to aspiring physician-researchers solely in medicine, as well as time set aside for laboratory research.

The newly named class includes: Miriam T. Jacobs, MD; Iris Lee, MD; and Paul Zolkind, MD.

Launched in 2020, the program represents the school’s commitment to addressing a national shortage of physician-scientists by fostering the career development of early-career physicians who treat patients but also wish to pursue biomedical research in the laboratory. .

Physician-scientists are considered essential to the development of new therapies and approaches to diagnosing and treating disease. While many physician-scientists hold medical degrees and doctorates, the Dean’s Scholars program aims to strengthen the research skills of those who have earned only medical degrees.

“Our Dean’s Fellows are excellent clinicians who have demonstrated outstanding aptitude and ambition in basic biomedical research,” said David H. Perlmutter, MD, executive vice chancellor for medical affairs, the Dean George and Carol Bauer of the Faculty of Medicine and the Spencer T. and Ann W. Olin Professor Emeritus. “We are thrilled to support their talents and help them achieve their career goals through this program. Their continued successes reinforce the medical school’s legacy as a leader in training influential physician-scientists.

The program is supported by a Physician-Scientist Institutional Award from the Burroughs Wellcome Fund, a non-profit organization that supports biomedical science through research and education. The School of Medicine and its departments also provide financial support for the program.

The three new Dean’s Scholars went through a competitive application process that involved interviews with experienced faculty and presentations of their proposed research projects.

Jacobs is a fourth-year fellow in the divisions of hematology and oncology. His research will focus on the use of cytokines – proteins essential for cell signaling – to enhance the ability of immune cells known as natural killer cells to fight cancer. His mentor is Todd A. Fehniger, MD, Ph.D.professor of medicine specializing in oncology, cell therapy and bone marrow transplantation.

Lee, a postdoctoral fellow in the Division of Rheumatology, aims to study how complement, a complex system of proteins that eliminates infectious agents, is involved in the development of autoimmune diseases such as rheumatoid arthritis. Specifically, she will examine how complement alters the function of immune cells such as B cells. Her mentors are Peggy L. Kendall, MDHead of the Division of Allergy and Immunology, and Virginia Minnich Professor of Medicine, and Christine Pham, MDChief of the Division of Rheumatology, and Guy and Ella Mae Magness Professor of Medicine.

Zolkind, assistant professor in the Department of Otorhinolaryngology – Head and Neck Surgery, will focus on the development of new therapeutic agents in preclinical models of head and neck cancer. Zolkind is also the chief of otolaryngology at John Cochran Veterans Hospital, which is affiliated with the University of Washington. His mentor is Ben Major, Ph.D.Alan A. and Edith L. Wolff Emeritus Professor of Cell Biology and Physiology.

“A dual MD/PhD degree is not a requirement to be a brilliant physician-scientist,” said Wayne M. Yokoyama, MD, Director of the Division of Physician-Scientists, Sam J. Levin and Audrey Loew Levin Professor of Arthritis Research, and Associate Dean. “However, medical-only physician-scientists face unique challenges in their career paths. The Dean’s Scholars program aims to guide them to success.

Yokoyama himself is internationally recognized for his research on natural killer cells.

Apps for the Dean’s Scholars Program 2023 will open this summer.

Scopio Labs Obtains FDA Clearance for Blood Smear Device Sun, 12 Jun 2022 07:09:44 +0000

Israel Society for Digital Microscopy Scopio Laboratoriesannounced this week that it has received 510(k) clearance from the US FDA for its X100HT device with Full-Field Peripheral Blood Smear (PBS) application to improve the accuracy and speed of hematology testing.

As hematological disorders As blood-related cancers, anemia, infections and allergies continue to grow worldwide, peripheral blood smear examinations have become critically important diagnostic tools for accurate analysis. Most of these tests are performed manually in most casts, however, Scopio’s Full-Field PBS Morphology Solution entirely eliminates the need for additional manual microscopic examination.

Scopio’s devices are capable of capturing large scanning areas at 100X magnification, unlike traditional handheld microscopy which is unable to simultaneously provide high resolution and wide field views. The X100HT can hold 30 slides and process up to 40 samples per hour, and is therefore well suited to meet the high throughput requirements of large hospitals and laboratories.

Founded in 2015 by Itai Hayut and Erez Na’aman, Scopio Labs’ platform automates the imaging of entire microscopy specimens into single high-resolution digital scans using state-of-the-art computational photography techniques. The company has also built and integrated various AI and remote consultation solutions for large and small laboratories and hospitals to improve diagnostic processes and reduce turnaround times. The company has raised $73 million to date from investors including OurCrowd, Aurum Ventures, and Ilex Medical, among others.

“We are excited to expand our suite of all-digital, AI-powered diagnostic platforms to accelerate PBS analysis, improve result consistency, and reduce exam time,” said Erez Naaman, CTO and co-founder of Scopio Labs. “At Scopio, we are determined to usher in the digital revolution in laboratory medicine. Our devices provide comprehensive remote capabilities for real-time diagnostic and treatment decisions, allowing experts to review, collaborate and consult from anywhere, anytime, using our powered apps by AI.

U.S. Direct-to-Consumer (DTC) Lab Testing Market Fri, 10 Jun 2022 11:08:36 +0000

Dublin, June 10, 2022 (GLOBE NEWSWIRE) — The “US Direct-to-Consumer (DTC) Lab Testing Market” report has been added to from offer.

Direct-to-consumer lab testing is also known as patient-ordered lab testing. A variety of tests are now available for direct-to-consumer testing.

The growing market for direct-to-consumer laboratory tests can drive awareness of health issues and genetic diseases, allowing patients to take a more proactive role in their healthcare.

With advances in technology, the completion of human genome sequencing, and the pressures of the pandemic, direct-to-consumer lab testing is becoming increasingly popular. Yet, clinical laboratories are an essential part of the healthcare industry. It is estimated that the vast majority of doctors’ diagnoses are the result of laboratory tests. In addition to diagnosing patients, clinical laboratory tests are performed to assess disease progression, monitor drug treatment and conditions, determine individual therapy, and several other reasons.

Several trends continue to shape the direct-to-consumer laboratory testing market, including growing demand for early disease detection and diagnosis, personalized medicine, importance of disease surveillance, consumer acceptance, and expanded technologies. . The report examines these and other key market trends.

Additionally, issues and trends explored in this report include:

  • Demography and aging of the population
  • Growing incidence of disease
  • Regulatory environment
  • Consumer-centred health care
  • Emphasis on preventive health care
  • Developments in personalized medicine
  • Mobile devices
  • Informed consent
  • Payment structure
  • Sales by distribution channel
  • Major Diagnostics and DTC Companies
  • Telehealth and DTC tests

Key companies profiled in the report include:

  • 23andme
  • Any lab test now
  • Color genomics
  • Direct laboratory services
  • EasyDNA
  • Everlywell
  • Laboratory Society of America
  • MyMedLab
  • Shadow Gut Health (formerly Thryve)
  • Quest Diagnosis
  • Request a trial

The base year for the data was 2021. The forecast years are 2022-2026 with compound annual growth rates (CAGR) provided for the periods 2021-2026 for each segment covered. The market analysis planned for 2021-2026 was largely based on demographic trends, new developments and innovative technologies.

Main topics covered:

Chapter 1: Executive Summary

  • Market size and growth
  • Scope and methodology
  • Major issues and trends affecting the market
  • Main market players
  • conclusion

Chapter 2: Overview

  • The American laboratory services industry
  • DTC Testing Market Growth
  • Structure of the laboratory industry in the United States
  • CLIA Laboratories Registration, Laboratories by Type
  • Direct-to-consumer testing
  • DTP in genetic testing
  • New opportunities in direct-to-consumer outlets
  • Dialysis clinics
  • Hospitals
  • Regulations in the laboratory industry
  • Waiver Certificate
  • Tests developed in the laboratory
  • State-by-State Assessments
  • Testing and services

Chapter 3: Direct-to-consumer routine clinical laboratory tests

  • Routine testing
  • Blood cell count
  • Cholesterol level test
  • diabetes test
  • HIV testing
  • Pregnancy test
  • Addiction tests
  • Urine analysis
  • COVID-19[feminine]
  • Saliva test
  • DTC Routine Clinical Laboratory Market Drivers and Barriers
  • Market size and growth
  • Competitive landscape

Chapter 4: Direct-to-consumer Genetic Laboratory Testing Market

  • Genetic research
  • DTC Genetic Testing Market Growth
  • Types of DTC Genetic Tests
  • Evolution of DTP Genetic Testing
  • DTC Genetic Testing Business Model
  • Market constraints
  • DTC Genetic Laboratory Testing Market Drivers and Barriers
  • Market size and growth
  • Competitive landscape

Chapter 5: Industry Drivers and Barriers

  • Issues and trends driving the direct-to-consumer market
  • Consumer-centred health care
  • Affordability and accessibility
  • Privacy
  • Aging of the population
  • Increase in chronic diseases
  • Emphasis on preventive health care
  • Regulatory environment
  • Regulatory route
  • Precision
  • Informed consent
  • Payment structure for direct-to-consumer lab testing
  • Direct payment to patients
  • Flexible Spending Accounts and Health Savings Accounts
  • Sales by distribution channel
  • Mobile devices
  • Major Diagnostics and DTC Companies
  • Telehealth and DTC tests

Chapter 6: Company Profiles

  • 23andme
  • Any lab test now
  • Color genomics
  • Direct laboratory services
  • EasyDNA
  • Everlywell
  • Laboratory Society of America
  • MyMedLab
  • Shadow Gut Health (formerly Thryve)
  • Quest Diagnosis
  • Request a trial

For more information on this report, visit

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and the latest trends.

		UC Davis Health opens new center focused on musculoskeletal research
		Wed, 08 Jun 2022 22:26:02 +0000


UC Davis Health officially opened its new Lawrence J. Ellison Oak Park Musculoskeletal Research Center with a ribbon-cutting ceremony on June 6. The new facility offers laboratories where faculty, residents, fellows, medical students, graduate and undergraduate students, and visiting researchers can conduct extensive interdisciplinary research in musculoskeletal tissue and cellular biomechanics, regeneration and repair.

David Lubarsky and Kent Leach discuss the new Musculoskeletal Research Center

“We are proud of our researchers across all disciplines who, amid the pandemic, have remained at the forefront of finding answers to medicine’s toughest questions and healthcare’s most complex problems.” , said David Lubarsky, CEO of UC Davis Health. “I deeply appreciate the power of discovery that will take place at this center and at all of UC Davis Health.”

The nearly 9,000 square foot research center houses a materials testing laboratory, cell and molecular biology facilities, tissue culture facilities, a microscopy laboratory and a microsurgery room. Computing facilities are also available for mathematical modeling of mechanical stresses in skeletal structures and implants.

“I am extremely excited as we open an important new chapter in the history of orthopedic surgery at such a critical time for our musculoskeletal science research programs, our educational efforts for emerging providers, and our patient community” , said R. Lor Randall, Chair of Orthopedic Surgery. “This center is further proof that we are creating and stimulating research growth opportunities for our faculty, trainees and medical students. We also recently achieved our highest ranking ever on the Blue Ridge NIH National Ranking, rising to 12, and experienced a fivefold increase in grant funding. I would like to thank everyone involved – donors, leaders, faculty and staff – who made this research center possible.

R. Lor Randall

I am incredibly excited as we open an important new chapter in the history of orthopedic surgery at such a critical time for our musculoskeletal science research programs, our educational efforts for emerging providers, and our patient community. R. Lor Randall

The Musculoskeletal Research Center will foster innovative research and partnerships and create exciting new research opportunities for faculty, students, residents and fellows. The ultimate goals are new discoveries and better patient care.

“Research centers like this are essential to fostering the curiosity and innovation that lead to breakthroughs in health care,” said Susan Murin, acting dean of the UC Davis School of Medicine. “The infrastructure and opportunities for collaboration that this center provides will help ensure that our medical school will continue to make groundbreaking discoveries that will enable us to deliver tomorrow’s healthcare today and improve the lives of patients and of the communities we serve.

As the only academic health center in the region, UC Davis Health is focused on harnessing the power of nationally ranked university-wide resources and research to tackle issues most urgent health problems facing the world today.

Two men and a woman walk through a laboratory
Kent Leach, R. Lor Randall and Susan Murin tour the new labs

In 2021, the School of Medicine achieved a new National Institutes of Health (NIH) research funding record with more than $194 million in grants. This is an increase of approximately $13 million over the previous year.

“I am thrilled to see the official launch of this research center that will advance the application of sophisticated methodologies and elegant models, and the desire to translate basic research into real hope for patients,” said Kim E. Barrett, Associate Dean for Research. . “Focusing research activities on orthopedic surgery will foster synergies between research groups and across the basic clinical-translational spectrum, providing new mechanistic understanding of musculoskeletal disorders.”

Recently and in a joint effort, the Departments of Orthopedic Surgery and Biomedical Engineering were awarded the prestigious National Institutes of Health (NIH) T32 Training Program Grant for their project titled MUsculoSkeletal Clinical Learning Experience (MUSCLE).

Kent Leaching

As researchers at this center, we must continue to capitalize on our expertise and imagine how we can broadly support the patients of tomorrow. Kent Leaching

The program will be based out of the Musculoskeletal Research Center and provide students with extensive investigative experience in laboratory research focused on musculoskeletal health.

“This research center and programs like the MUSCLE T32 research grant will expand our knowledge, enhance our educational offerings, and ultimately enable us to better understand the big picture of musculoskeletal health,” said Kent Leaching, Lawrence J. Ellison Endowed Professor of Musculoskeletal Research and Vice President of Orthopedic Surgery Research. “As researchers at this center, we must continue to capitalize on our expertise and imagine how we can broadly support the patients of tomorrow.”

The Lawrence J. Ellison Oak Park Musculoskeletal Research Center is located at 2700 Stockton BLVD, Sacramento. To learn more, visit the Department of Orthopedic Surgery homepage.